RESEARCH PROFILE
WOLVERINE
BPC-157 + TB-500 • Tissue Repair Research Blend
The Wolverine Stack combines BPC-157 and TB-500 in a single research framework focused on tissue repair, cell migration, angiogenic signaling, and connective-tissue biology.
The combination is based on the hypothesis that the compounds may influence different but potentially complementary repair pathways. However, the Wolverine combination itself has not been validated in human clinical trials.
INVESTIGATIONAL • NOT FDA APPROVED • COMBINATION NOT CLINICALLY VALIDATED
WOLVERINE AT A GLANCE
Category
Tissue repair and regenerative research blend
Components
BPC-157 + TB-500
Research Rationale
Potentially complementary tissue-repair pathways
Primary Research Focus
Cell migration • Angiogenesis • Tendon and connective-tissue biology • Tissue remodeling
Evidence Base
Primarily preclinical and compound-level evidence
Combination Evidence
No published human clinical trial validating BPC-157 + TB-500 together
Regulatory Status
Not FDA approved
IMPORTANT DISTINCTION
The Wolverine Stack is a research combination, not an FDA-approved treatment.
BPC-157 and TB-500 have separate proposed mechanisms and separate evidence bases.
Combining them does not establish that the combination is more effective than either compound alone.
The Project source specifically characterizes the proposed synergy as theoretical rather than established.
WHAT IS THE WOLVERINE STACK?
The Wolverine Stack is a commonly used research name for pairing BPC-157 and TB-500 within a tissue-repair-focused research framework.
The name is borrowed from the comic-book character associated with rapid healing. It is not a clinical designation and does not imply that the combination has been shown to accelerate healing in humans.
BPC-157
BPC-157 is a synthetic 15 amino acid peptide derived from a sequence associated with human gastric juice.
Preclinical research has explored BPC-157 in relation to:
Tendon and ligament biology
Angiogenic signaling
Growth-factor pathways
Cell migration
Gastrointestinal tissue research
Wound and tissue repair
TB-500
TB-500 is described in the Project source as a synthetic fragment associated with thymosin beta-4 biology.
Research interest centers on:
Actin dynamics
Cell migration
Tissue remodeling
Angiogenesis
Inflammatory signaling
WHY COMBINE THEM?
The research rationale is mechanistic complementarity.
BPC-157 and TB-500 are proposed to influence different aspects of tissue repair rather than simply duplicating the same pathway.
That creates an interesting research hypothesis.
It does not establish clinical synergy.
MECHANISM OF ACTION
The Wolverine Stack combines two compounds with different proposed biological targets.
BPC-157
Preclinical research suggests BPC-157 may influence several signaling systems associated with tissue repair.
Areas of investigation include:
ANGIOGENIC SIGNALING
BPC-157 has been studied in relation to vascular endothelial growth factor and pathways involved in new blood-vessel formation.
CELL MIGRATION
Experimental research suggests effects on cellular migration involved in tissue-repair processes.
GROWTH-FACTOR SIGNALING
Research has explored interactions involving pathways such as VEGF, FAK, ERK and related repair signaling.
TENDON & CONNECTIVE-TISSUE BIOLOGY
Animal studies have investigated tendon-to-bone healing, ligament injury and other connective-tissue models.
TB-500
The proposed TB-500 mechanism centers more heavily on actin-related cell behavior and tissue remodeling.
ACTIN DYNAMICS
Thymosin beta-4 biology is closely associated with regulation of actin, a structural protein essential to cell shape and movement.
CELL MIGRATION
Thymosin beta-4 research has demonstrated effects on migration of endothelial cells and other cells involved in tissue repair.
ANGIOGENESIS
Preclinical research has demonstrated pro-angiogenic activity associated with thymosin beta-4 pathways.
TISSUE REMODELING
These mechanisms have generated research interest in wound, connective-tissue and recovery models.
THE COMBINATION HYPOTHESIS
The proposed rationale can be summarized as:
BPC-157
Local repair signaling + growth-factor and angiogenic pathways
TB-500
Actin regulation + systemic cell migration and remodeling pathways
The Project profile therefore describes the combination as potentially providing broader mechanistic coverage.
IMPORTANT MECHANISM LIMITATION
A biologically plausible mechanism does not demonstrate a clinical benefit.
There is no published human trial showing that combining BPC-157 with TB-500 produces superior tissue repair, recovery, tendon healing or other clinical outcomes.
WHAT THE RESEARCH SHOWS
WOLVERINE COMBINATION EVIDENCE
The most important evidence limitation is straightforward:
There is no direct clinical evidence validating the Wolverine Stack as a combination.
The Project profile identifies no published human trial that has tested BPC-157 + TB-500 together.
Clinical claims must therefore come from the evidence for the individual compounds and must not be represented as evidence for the combination.
BPC-157 EVIDENCE
The BPC-157 literature is dominated by preclinical research.
Animal and laboratory studies have investigated:
Tendon healing
Ligament injury
Muscle injury
Gastrointestinal tissue
Angiogenesis
Cell migration
Wound repair
The Project source also references a 2025 systematic review of the BPC-157 musculoskeletal literature.
That review found that the available literature remained predominantly animal-based.
The Project profile notes that the human literature is very limited and includes small observational or case-based reports rather than robust randomized clinical evidence.
TB-500 / THYMOSIN BETA-4 EVIDENCE
The evidence requires another important distinction.
Much of the published literature commonly associated with TB-500 actually involves full-length thymosin beta-4, rather than the shorter TB-500 fragment.
Full-length thymosin beta-4 has been investigated in:
Human Phase I safety research
Venous-ulcer research
Ophthalmic research
Wound-healing models
Preclinical research has also explored:
Endothelial cell migration
Angiogenesis
Cardiac repair
Corneal healing
Connective-tissue biology
The Project source states that the TB-500 fragment itself has not completed a published randomized clinical trial.
TENDON & CONNECTIVE-TISSUE RESEARCH
Both compounds are frequently associated with tendon and connective-tissue research, but the evidence comes largely from animal and laboratory models.
These studies provide a biological rationale for continued research.
They do not establish that Wolverine heals human tendon, ligament, muscle or joint injuries.
IMPORTANT EVIDENCE LIMITATIONS
No published human trial has established the efficacy of the BPC-157 + TB-500 combination.
Evidence for the individual compounds does not automatically validate the blend.
Animal findings cannot be assumed to produce equivalent effects in humans.
Research involving full-length thymosin beta-4 should not automatically be attributed to the TB-500 fragment.
There is also no clinical evidence demonstrating that Wolverine is superior to either compound used independently.
SAFETY & RESEARCH CONSIDERATIONS
There is no established human safety profile for the Wolverine Stack as a combination.
Safety therefore has to be considered from the limited compound-level evidence, theoretical mechanisms, product quality, and the absence of long-term combination data.
BPC-157
The Project source describes human BPC-157 safety information as very limited.
Available human reports are insufficient to establish a comprehensive adverse-event profile or long-term safety.
TB-500
Direct human safety information for the TB-500 fragment is also extremely limited.
Some human safety research exists for full-length thymosin beta-4, but those findings should not automatically be transferred to TB-500.
INJECTION-SITE EFFECTS
Research-community reports associated with injectable peptide products include:
Redness
Localized swelling
Transient bruising
Irritation
Occasional sterile abscesses
These observations do not constitute a controlled clinical safety profile.
ANGIOGENESIS & THEORETICAL CANCER CONCERN
Both compounds are associated with biological pathways involving angiogenesis.
Angiogenesis is an important part of normal tissue repair, but it is also involved in tumor biology.
The Project source therefore identifies a theoretical concern in individuals with active or prior cancer.
This is a mechanistic concern rather than evidence that Wolverine causes cancer.
Long-term human data are insufficient to determine the clinical relevance.
UNKNOWN COMBINATION EFFECTS
Even when two compounds have individually studied mechanisms, combining them may introduce:
Additive effects
Unexpected interactions
Different pharmacodynamic behavior
Different safety considerations
Those possibilities have not been adequately characterized for Wolverine in humans.
PRODUCT QUALITY
Research-use peptide quality represents an additional independent risk.
Potential issues include:
Incorrect identity
Incorrect concentration
Contamination
Degradation
Sterility failure
Lot-to-lot variability
Lot-specific analytical testing can characterize the tested sample but does not establish clinical safety or efficacy.
SPORT & COMPETITION
The Project source identifies BPC-157 and TB-500 as prohibited under applicable World Anti-Doping Agency rules.
Competitive athletes should consult current anti-doping regulations rather than assuming research status makes these substances permissible.
REGULATORY CONTEXT
WOLVERINE IS NOT FDA APPROVED
There is no FDA-approved BPC-157 + TB-500 combination drug.
Neither the Wolverine name nor combining the compounds creates an FDA-approved therapy.
BPC-157
The Project regulatory material identifies BPC-157 as not FDA approved.
TB-500
TB-500 is likewise not FDA approved.
The Project source documents evolving FDA compounding-related regulatory activity involving TB-500-related substances.
2026 COMPOUNDING DEVELOPMENTS
Your Wolverine profile documents that both compounds had been associated with FDA's 503A Category 2 compounding review process.
The source further notes changes to Category 2 during 2026 and subsequent Pharmacy Compounding Advisory Committee consideration.
These regulatory developments concern compounding policy and bulk-drug-substance evaluation.
They do not constitute FDA approval or establish clinical efficacy.
IMPORTANT REGULATORY DISTINCTION
Regulatory review is not regulatory approval.
Removal from a compounding category does not establish safety or efficacy.
Research findings do not establish an approved therapeutic indication.
The Wolverine Stack remains an unapproved research combination.
ANALYTICAL DOCUMENTATION
Croix maintains available third party analytical documentation for specific samples and lots represented in its research library.
BPC-157 + TB-500 10 MG
Laboratory
Optiq Health Labs
Sample Name
bpc 157 tb 500 10mg
Lot
kizn072426
Sample Matrix
Lyophilized Peptide
Sample ID
1268.OPT.260910
Report Date
September 18, 2026
Intended Use
Research Use Only
Reported Net Content
BPC-157: 5.03 mg/vial
TB-500: 4.99 mg/vial
Total reported peptide content: 10.02 mg/vial
Reported Purity
99.1%
Identity
BPC-157 + TB-500
LC-MS confirmation • Tested
Endotoxin
Pass • LAL ≤ 0.05 EU/mg
Sterility
Pass • USP <71> • No Growth
The laboratory report identifies the tested material as BPC-157 + TB-500 and reports 5.03 mg/vial and 4.99 mg/vial respectively, with 99.1% purity, LC-MS identity confirmation, endotoxin pass, and sterility pass. COAs-2(2)
IMPORTANT COA LIMITATION
Analytical results apply only to the specific sample identified in the corresponding laboratory report.
A Certificate of Analysis for one sample does not establish the composition, purity, sterility, safety, efficacy, or characteristics of another sample, lot, batch, or product.
The laboratory specifically states that its results relate only to the sample received and tested and do not represent or warrant another sample, lot, batch, product, or material. COAs-2(2)
A passing COA also does not establish FDA approval, clinical efficacy, or medical suitability.
SELECTED RESEARCH & REFERENCES
BPC-157 RESEARCH
Vanežić A, et al.
Systematic review examining BPC-157 in orthopedic and musculoskeletal research.
The Project source uses this review to contextualize the predominantly preclinical nature of the BPC-157 evidence base.
Krivic A, et al.
Research involving BPC-157 and tendon-healing models.
Preclinical connective-tissue research.
Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS.
Research examining BPC-157 and tendon fibroblast outgrowth, survival and cell migration.
Preclinical mechanistic evidence.
Staresinic M, et al.
Research involving BPC-157 in muscle-healing models.
Preclinical tissue-repair evidence.
THYMOSIN BETA-4 / TB-500 RESEARCH
Malinda KM, Goldstein AL, Kleinman HK.
Research examining thymosin beta-4 and endothelial-cell migration.
Foundational mechanistic research relevant to cell migration and angiogenesis.
Smart N, et al.
Research examining thymosin beta-4 and epicardial progenitor-cell activation.
Preclinical regenerative biology.
Bock-Marquette I, et al.
Research examining thymosin beta-4, cardiac-cell migration, survival and repair.
Preclinical mechanistic research.
Ruff D, Crockford D, Girardi M, Zhang Y.
Human Phase I research evaluating intravenous full-length thymosin beta-4 in healthy volunteers.
Important human safety context for the parent peptide rather than direct Wolverine evidence.
REGULATORY & ANTI-DOPING REFERENCES
U.S. Food & Drug Administration
FDA compounding and Pharmacy Compounding Advisory Committee materials concerning BPC-157 and TB-500-related substances.
World Anti-Doping Agency
Current Prohibited List and applicable non-approved substance provisions.
EVIDENCE NOTE
These references provide compound-level biological and regulatory context.
They should not be represented as clinical evidence for the Wolverine combination itself.
No published human clinical trial cited in the Project source has tested BPC-157 and TB-500 together as the Wolverine Stack.
RESEARCH & EDUCATIONAL INFORMATION
This profile is provided for research and educational reference. It does not constitute individualized medical advice or establish the Wolverine Stack as safe or effective for personal use.
BPC-157 and TB-500 are not FDA-approved therapies, and the combined Wolverine Stack has not been validated in published human clinical trials.
Much of the evidence associated with these compounds is derived from animal, laboratory, mechanistic, or limited compound-specific research. Human evidence involving full-length thymosin beta-4 should not automatically be attributed to the TB-500 fragment.
The proposed complementary relationship between BPC-157 and TB-500 is a research hypothesis and should not be interpreted as proven clinical synergy.
Analytical documentation presented by Croix applies only to the specific samples and lots identified in corresponding laboratory reports.